Omnicell to Release Fourth Quarter and Full Year 2024 Financial Results on February 6, 2025
Omnicell (Nasdaq:OMCL), a company focused on transforming pharmacy and nursing care delivery models, has announced it will release its fourth quarter and full year 2024 financial results before market open on Thursday, February 6, 2025.
The company will host a conference call and webcast to discuss these results at 8:30 a.m. ET on the same day. Interested parties can join via phone using the numbers (800) 715-9871 (U.S.) or (646) 307-1963 (international) with Conference ID 2515873. A live and archived webcast will be available through Omnicell's Investor Relations website.
Omnicell (Nasdaq:OMCL), un'azienda dedicata a trasformare i modelli di consegna dei servizi farmaceutici e di assistenza infermieristica, ha annunciato che pubblicherà i propri risultati finanziari del quarto trimestre e dell'intero anno 2024 prima dell'apertura del mercato il giovedì 6 febbraio 2025.
L'azienda organizzerà una conference call e un webcast per discutere di questi risultati alle 8:30 a.m. ET dello stesso giorno. Le parti interessate possono partecipare telefonicamente utilizzando i numeri (800) 715-9871 (USA) o (646) 307-1963 (internazionale) con ID Conferenza 2515873. Un webcast dal vivo e la registrazione saranno disponibili attraverso il sito web delle Relazioni con gli Investitori di Omnicell.
Omnicell (Nasdaq:OMCL), una empresa centrada en transformar los modelos de prestación de servicios farmacéuticos y de enfermería, ha anunciado que publicará sus resultados financieros del cuarto trimestre y del año completo 2024 antes de la apertura del mercado el jueves 6 de febrero de 2025.
La empresa llevará a cabo una conferencia telefónica y un webcast para discutir estos resultados a las 8:30 a.m. ET del mismo día. Las partes interesadas pueden unirse por teléfono utilizando los números (800) 715-9871 (EE.UU.) o (646) 307-1963 (internacional) con ID de Conferencia 2515873. Un webcast en vivo y grabado estará disponible a través del sitio web de Relaciones con Inversionistas de Omnicell.
Omnicell (Nasdaq:OMCL)은 약국 및 간호 서비스 제공 모델을 혁신하는 데 집중하는 회사로, 2024년 4분기 및 연간 재무 결과를 2025년 2월 6일 목요일 시장 개장 전에 발표할 것이라고 밝혔습니다.
회사는 같은 날 오전 8:30 ET에 이러한 결과를 논의하기 위한 컨퍼런스 콜 및 웹캐스트를 진행합니다. 관심 있는 분들은 (800) 715-9871 (미국) 또는 (646) 307-1963 (국제) 번호로 전화에 접속하여 회의 ID 2515873을 사용하여 참여할 수 있습니다. Omnicell의 투자자 관계 웹사이트를 통해 실시간 및 기록된 웹캐스트가 제공됩니다.
Omnicell (Nasdaq:OMCL), une entreprise axée sur la transformation des modèles de prestation de soins pharmaceutiques et infirmiers, a annoncé qu'elle publiera ses résultats financiers du quatrième trimestre et de l'année complète 2024 avant l'ouverture du marché le jeudi 6 février 2025.
L'entreprise organisera une conférence téléphonique et un webcast pour discuter de ces résultats à 8h30 ET le même jour. Les parties intéressées peuvent participer par téléphone en utilisant les numéros (800) 715-9871 (États-Unis) ou (646) 307-1963 (international) avec l'ID de conférence 2515873. Un webcast en direct et enregistré sera disponible sur le site web des Relations avec les Investisseurs d'Omnicell.
Omnicell (Nasdaq:OMCL), ein Unternehmen, das sich auf die Transformation von Modellen zur Bereitstellung von Apotheken- und Pflegeleistungen konzentriert, hat angekündigt, dass es seine Finanzergebnisse für das vierte Quartal und das Gesamtjahr 2024 vor Markteröffnung am Donnerstag, den 6. Februar 2025 veröffentlichen wird.
Das Unternehmen wird am selben Tag um 8:30 Uhr ET eine Telefonkonferenz und einen Webcast abhalten, um diese Ergebnisse zu diskutieren. Interessierte Parteien können sich per Telefon unter der Nummer (800) 715-9871 (USA) oder (646) 307-1963 (international) mit der Konferenz-ID 2515873 einwählen. Ein Live- und archivierter Webcast ist über die Investor Relations-Website von Omnicell verfügbar.
- None.
- None.
All interested parties are invited to listen to the live call and presentation by dialing (800) 715-9871 in the
About Omnicell
Since 1992, Omnicell has been committed to transforming pharmacy care through outcomes-centric innovation designed to optimize clinical and business outcomes across all settings of care. Through a comprehensive portfolio of robotics, smart devices, software, and expert services, Omnicell solutions are helping healthcare facilities worldwide to uncover cost savings, improve labor efficiency, establish new revenue streams, enhance supply chain control, support compliance, and move closer to the industry-defined vision of the Autonomous Pharmacy. To learn more, visit omnicell.com.
OMNICELL and the Omnicell logo are registered trademarks of Omnicell, Inc. or one of its subsidiaries.
OMCL-E
View source version on businesswire.com: https://www.businesswire.com/news/home/20250113205680/en/
Kathleen Nemeth
Senior Vice President, Investor Relations
ir@omnicell.com
Source: Omnicell, Inc.
FAQ
When will Omnicell (OMCL) release its Q4 and full year 2024 earnings?
What time is Omnicell's (OMCL) Q4 2024 earnings call?
How can investors access Omnicell's (OMCL) Q4 2024 earnings call?
Where can I find the webcast of Omnicell's (OMCL) Q4 2024 earnings call?
